{"id":2055,"date":"2024-06-14T00:14:47","date_gmt":"2024-06-13T22:14:47","guid":{"rendered":"https:\/\/proacta.pl\/ofertapubliczna\/"},"modified":"2025-09-18T22:40:41","modified_gmt":"2025-09-18T20:40:41","slug":"public-offering-of-proacta-s-a-series-n-shares","status":"publish","type":"page","link":"https:\/\/proacta.pl\/en\/public-offering-of-proacta-s-a-series-n-shares\/","title":{"rendered":"Public offering of Proacta S.A. series N shares."},"content":{"rendered":"\n
\n

This material is for promotional and informational purposes only and in no way constitutes a recommendation to purchase shares or a basis for deciding to acquire shares in Proacta S.A. The Offering Document, prepared in connection with the public offering of Proacta S.A. shares, is the only legally binding document containing information about the Company and the public offering of the Company’s shares in Poland.<\/em><\/em><\/p>\n<\/div><\/div>\n\n\n\n

\n

Registration deadline<\/em><\/h2>\n\n\n\n

Deadline for registration under invitations issued by the Management Board<\/em><\/p>\n\n\n\n

July 23 \u2013 August 6, 2024<\/em><\/p>\n\n\n\n

How to register<\/a><\/p>\n\n\n\n

\n
\n
Formularz zapisu dla os\u00f3b prawnych<\/a><\/div>\n\n\n\n
Formularz zapisu dla os\u00f3b fizycznych<\/a><\/div>\n\n\n\n
Dokument ofertowy<\/a><\/div>\n\n\n\n
Suplement nr 1<\/a><\/div>\n\n\n\n
Suplement nr 2<\/a><\/div>\n\n\n\n
Suplement nr 3<\/a><\/div>\n\n\n\n
Prezentacja inwestorska<\/a><\/div>\n\n\n\n
Wykaz zmian nr 1<\/a><\/div>\n\n\n\n
Wykaz zmian nr 2<\/a><\/div>\n<\/div>\n<\/div><\/div>\n<\/div><\/div>\n\n\n\n
\n

Proacta S.A. is a public company listed on the ASO New Connect market operated by the Warsaw Stock Exchange.<\/p>\n\n\n\n

\"\"<\/figure>\n<\/div><\/div>\n\n\n\n
\n

Description of activities<\/h2>\n\n\n\n

Proacta S.A. is the parent company of the Proacta Capital Group, operating in the field of bioinformatics and artificial intelligence-based medicine in Poland. The company provides technologically advanced services, focusing on the analysis of medical and genetic data, bioinformatics, and the design and creation of predictive models based on artificial intelligence.<\/p>\n\n\n\n

In addition, as part of its diversification strategy, the Issuer provides programming services, creating dedicated software for business entities (i.e., in a B2B formula). Group structureThe Issuer forms a Capital Group consisting of two subsidiaries: Databion sp. z o.o. and VE Space sp. z o.o. Proacta S.A. holds 100% of the share capital and 100% of the votes at the General Meeting of the aforementioned subsidiaries. The subsidiaries are excluded from consolidation pursuant to Article 58 of the Accounting Act.
<\/p>\n<\/div><\/div>\n\n\n\n

\n

Group Structure<\/h2>\n\n\n\n

The Issuer forms a Capital Group comprising two subsidiaries: Databion sp. z o.o. and VE Space sp. z o.o. Proacta S.A. holds 100% of the share capital and 100% of the votes at the General Meeting of Shareholders of the aforementioned subsidiaries.<\/p>\n\n\n\n

Subsidiaries are excluded from consolidation pursuant to Article 58 of the Accounting Act.<\/h3>\n\n\n\n
\"\"<\/figure>\n<\/div><\/div>\n\n\n\n
\n

Market for business activities<\/h2>\n\n\n\n

The bioinformatics market, driven by growing demand for integrated solutions in data processing, integration, and management, as well as the development of artificial intelligence (AI) and machine learning (ML) applications, plays a key role in areas such as healthcare, clinical diagnostics, and precision medicine.<\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

This market reached a value of $12.3 million in 2023, and its estimated value by 2032 will be $36.2 billion with a CAGR of 12.3%, representing a 194% increase over 9 years (source: Imarc Services Private Limited).<\/p>\n<\/div><\/div>\n\n\n\n

\n
\n<\/div><\/div>\n\n\n\n
\n

Business segments<\/h2>\n\n\n\n

The Issuer’s main area of activity is the provision of services based on advanced technologies in the following areas<\/h3>\n\n\n\n
\"\"<\/figure>\n\n\n\n

Despite the Issuer’s involvement in medical projects, the Company has been implementing IT projects for over 15 years (operating as Proacta Sp. z o.o. before 2023) as part of programming services and IT specialist outsourcing. The Group has completed over 100 projects for 60 business clients related to the design, production, development, and maintenance of IT systems for clients from the private and public sectors. As of March 31, 2024, the Issuer generated all of its sales revenue in the amount of PLN 1.6 million from the above-mentioned business segment.<\/p>\n<\/div><\/div>\n\n\n\n

\n

Services for the medical sector<\/h2>\n\n\n\n

In 2018, the Issuer (then operating as Proacta Sp. z o.o.) began work on its proprietary Databion technology platform. It is a multifunctional analytical platform for the collection, processing, and analysis of medical and genetic data.<\/p>\n\n\n\n

In connection with the continuous development of the platform, the Company has created a number of proprietary solutions based on the experience gained during its development and through the implementation of research and development projects. These are products dedicated to the medical sector and individual patients, which use advanced information technologies, including artificial intelligence (AI) and machine learning (ML).<\/p>\n\n\n\n

\n
\n
\"\"<\/figure>\n\n\n\n

I take care of myself Smart Lab<\/h4>\n<\/div>\n\n\n\n
\n
\"\"<\/figure>\n\n\n\n

Digital Breast Cancer Unit<\/h4>\n<\/div>\n\n\n\n
\n
\"\"<\/figure>\n\n\n\n

Patient Portal<\/h4>\n<\/div>\n<\/div>\n<\/div><\/div>\n\n\n\n

The Issuer’s customers and key partnerships<\/h2>\n\n\n\n

The company has cooperated and implemented projects for many business entities from various industries, including:<\/p>\n\n\n\n

Olimp Laboratories, PPUC Envelo, Simple, Bank Guarantee Fund, Integrated Solutions, Ministry of the Environment, Trusted Software Services, Union Parts, MBB Logistics, Univeg, Ministry of Justice, O\u017c\u00f3g i Tomczykowski, Mayland, Med4Med, EO Networks, Helping Hand, Fratria, Lobster, Credit Information Bureau, TLS \u2013 Boca Systems, Agency for Restructuring and Modernization of Agriculture, Grabowski i Wsp\u00f3lnicy, Merlin Group, Florexpol, Estelligence, Agersol, Netbulls, Baltrafood, Sygnity, AD Invest, Red Ocean, Fazbud Instal, Gas-Trading, Green Energy, Business Consulting Group, Institute of Environmental Protection, Si\u00f3demka, Kasa Stefczyka, District Court in Warsaw, Tech Soft, Tomax, National Center for Agricultural Support.<\/p>\n\n\n\n

In addition, the Company has cooperated and continues to cooperate with entities from the medical and medical-related industries, including<\/p>\n\n\n\n

the Medical University of \u0141\u00f3d\u017a, the Lublin Oncology Center, the Opole Oncology Center, TrichoLAB, the CODE Medical Center, Diagnostyka, Medidesk, the e-Health Center (in cooperation with Trusted Software Services), and Neuca.<\/p>\n\n\n\n

Employment structure<\/h2>\n\n\n\n

As at March 31, 2024, the Issuer employed and cooperated with 47 persons, including 3 persons performing functions by virtue of appointment, 13 persons performing work under employment contracts, 30 persons providing services under B2B contracts, and one person providing services under a civil law contract.<\/p>\n\n\n\n

\n

Shareholder structure<\/h2>\n\n\n\n

Shareholders \u2013 before and after the offering<\/p>\n\n\n\n

Before the offer<\/h3>\n\n\n\n
\"\"<\/figure>\n\n\n\n

After the offer<\/h3>\n\n\n\n
\"\"<\/figure>\n<\/div><\/div>\n\n\n\n

Development strategy<\/h2>\n\n\n\n

2Q 2024<\/h4>\n\n\n\n

Launch of the SmartLab module as part of the \u201cI take care of myself\u201d platform for consumers. Promotional campaign for the new solution.<\/p>\n\n\n\n

3\/4Q 2024<\/h4>\n\n\n\n

Introduction of the SmartLab module for businesses, i.e., medical institutions and companies. Promotional campaign for the new product. Completion of the first DBCU test projects.<\/p>\n\n\n\n

1Q 2025<\/h4>\n\n\n\n

Launch of the Patient Portal in a white label format.<\/p>\n\n\n\n

2Q 2025<\/h4>\n\n\n\n

Launch of the DCCU program focused on the treatment of colorectal cancer. Launch of the SmartLab service for primary health care (POZ).<\/p>\n\n\n\n

4Q 2025<\/h4>\n\n\n\n

Introduction of the DLCU program focused on the treatment of lung cancer.<\/p>\n\n\n\n

Public offering<\/h2>\n\n\n\n

The subject of the Public Offering are ordinary bearer shares of Proacta S.A. (\u201cCompany\u201d) series N with a nominal value of PLN 0.50 each, in a total number of 2 to 4,049,139 shares, at an issue price of PLN 0.50. The offering is carried out with preemptive rights.<\/p>\n\n\n\n

\n

Offer schedule<\/h2>\n\n\n\n
\"\"<\/figure>\n<\/div><\/div>\n\n\n\n
\n

Offer schedule<\/h2>\n\n\n\n

A detailed description of the issuance objectives is provided in the Offering Document dated June 14, 2024, in Chapter III, section 7.14.
The Issuer will issue between 2 (two) and 4,049,139 (four million forty-nine thousand one hundred thirty-nine) series N shares offered under preemptive rights at an issue price of PLN 0.50 (fifty groszy) plans to raise from PLN 1 (one zloty) to PLN 2,024,569.50 (two million twenty-four thousand five hundred sixty-nine zlotys and fifty pennies).<\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

The issuance objectives listed above have been ranked according to the priorities assigned to them by the Issuer, which means that individual objectives will be achieved provided that the appropriate amount of financing is obtained from the issuance of series N shares.
The Issuer’s Management Board notes that the above-described issue objectives may be subject to change in terms of amounts and dates of implementation if the Issuer decides that the implementation of other objectives will contribute more effectively to the Company’s development.
If an objective is identified which, in the opinion of the Management Board, will better contribute to the Company’s growth, the Management Board may decide to allocate the funds raised to another objective. In such a situation, the Management Board will present an alternative objective that fits in with the assumed development strategy.
If the planned funds from the issue of series N shares in the amount of PLN 2,024,569.50 are not obtained, the Issuer intends to achieve the above-mentioned issue objectives from the proceeds of its current operations.<\/p>\n<\/div><\/div>\n\n\n\n

\n\n\n\n
\n

How to subscribe?<\/h2>\n\n\n\n

Management Board Tranche<\/h3>\n\n\n\n

To participate in the offer in the tranche of invitations issued by the Management Board, you must be a client of DM INC S.A. (hereinafter referred to as the \u201cBrokerage House\u201d) between July 23 and August 6, 2024. To do so, you must conclude an order acceptance and transmission agreement (hereinafter referred to as the \u201cOAT Agreement\u201d) with the Brokerage House and, within its scope, undergo an assessment of the suitability of the brokerage service in terms of acceptance and transmission, which will determine whether you are in the target group of recipients for the offered shares.<\/p>\n\n\n\n

I. For future clients of the Brokerage House:<\/h4>\n\n\n\n

Step 1:<\/strong><\/p>\n\n\n\n

Write to Dom Maklerski INC S.A. using the form at the bottom of the page: https:\/\/dminc.pl\/kontakt<\/a>, entering Proacta in the subject line. A Brokerage House employee will contact you.<\/p>\n\n\n\n

Step 2:<\/strong><\/p>\n\n\n\n

Complete the procedure to prepare for the conclusion of the PPZ Agreement. If the verification is positive, sign the agreement in accordance with the instructions provided by an employee of Dom Maklerski INC.<\/p>\n\n\n\n

Step 3:<\/strong><\/p>\n\n\n\n

Fill out the Registration Form on this page and sign it with a qualified signature or ePUAP trusted profile and send it electronically to the following email address: emisje@dminc.pl<\/a> or sign the form in person and deliver it to the headquarters of Dom Maklerski (ul. Abpa A. Baraniaka 6 in Pozna\u0144) or the Customer Service Point (ul Wsp\u00f3lna 35 lok. 12, Warsaw).<\/p>\n\n\n\n

Step 4:<\/strong><\/p>\n\n\n\n

Pay the full amount for the subscription to the bank account of Dom Maklerski INC S.A. indicated in the Subscription Form by August 6, 2024, inclusive.<\/p>\n\n\n\n

Concluding a PPZ agreement with Dom Maklerski is free of charge. Dom Maklerski does not charge any commission on the transactions it mediates.<\/p>\n\n\n\n

II. For current clients of the Brokerage House:<\/h4>\n\n\n\n

Step 1:<\/strong><\/p>\n\n\n\n

Write to Dom Maklerski INC S.A. using the form at the bottom of the page: https:\/\/dminc.pl\/kontakt<\/a>, entering Proacta in the subject line. A Brokerage House employee will contact you.<\/p>\n\n\n\n

Step 2:<\/strong><\/p>\n\n\n\n

Fill in the Registration Form on this page and sign it with a qualified signature or a trusted ePUAP profile and send it electronically to the following email address: emisje@dminc.pl<\/a> or sign the form in person and deliver it to the headquarters of Dom Maklerski INC S.A. (ul. Abpa A. Baraniaka 6 in Pozna\u0144) or the Customer Service Point (ul Wsp\u00f3lna 35 lok. 12, Warsaw).<\/p>\n\n\n\n

Step 3:<\/strong><\/p>\n\n\n\n

Pay the full amount for the subscription to the bank account of Dom Maklerski INC S.A. indicated in the Subscription Form by August 6, 2024, inclusive.<\/p>\n\n\n\n

The correctness of the subscription is determined by the payment for the shares being credited to the Brokerage House’s bank account by August 6, 2024. If the payment is not credited, the subscription will be invalid.<\/p>\n\n\n\n

Subscriptions for the remaining Series N Shares not covered by the preemptive right and after taking into account additional subscriptions submitted by investors selected by the Management Board will be accepted between July 23, 2024, and August 6, 2024.<\/p>\n\n\n\n

Pursuant to Article 436 \u00a7 of the Commercial Companies Code, Series N Shares will be allocated by the Issuer’s Management Board at its discretion, but at a price not lower than their issue price.<\/p>\n\n\n\n

Subscriptions for the remaining Series N Shares submitted by investors selected by the Management Board will be accepted by Dom Maklerski INC S.A. (the Intermediary) in a manner agreed with the Intermediary.<\/p>\n\n\n\n

Detailed distribution rules are described in Chapter III, point 7 of the Offering Document dated June 14, 2024.<\/strong><\/p>\n\n\n\n

Preemptive Rights and Additional Subscription Tranche\u2028\u2013 completed on July 10, 2024.<\/h3>\n\n\n\n

Step 1:<\/strong><\/p>\n\n\n\n

A shareholder holding shares in the Company at the end of June 11, 2024, is entitled to exercise the Preemptive Right.<\/p>\n\n\n\n

Step 2:<\/strong><\/p>\n\n\n\n

After logging into your brokerage account, you should see a tab labeled \u201cIssue with Preemptive Rights,\u201d \u201cPublic Offerings,\u201d or similar.<\/p>\n\n\n\n

Step 3:<\/strong><\/p>\n\n\n\n

After entering the appropriate tab, you must submit your subscription in accordance with the procedure applicable to each brokerage house.<\/p>\n\n\n\n

Subscriptions for Series N Shares based on Preemptive Rights must be submitted during the Subscription Period at branches (customer service points) of:<\/p>\n\n\n\n

\u00a7 the brokerage house (office) maintaining the securities account on which the Preemptive Rights are registered,<\/p>\n\n\n\n

\u00a7 the brokerage house (office) indicated by the bank maintaining the securities account on which the Preemptive Rights are registered.<\/p>\n\n\n\n

Subscriptions for Series N Shares under preemptive rights and additional subscriptions will commence on June 18, 2024, and will be accepted until July 10, 2024.<\/p>\n\n\n\n

Detailed distribution rules are described in Chapter III, point 7 of the Offering Document dated June 14, 2024.<\/p>\n\n\n\n

Subscriptions based on Preemptive Rights and Additional Subscriptions may be submitted during the business hours of the institutions accepting subscriptions and paid for in accordance with the rules of operation of those institutions. Subscribers must take into account additional restrictions imposed by institutions accepting subscriptions for Series N Shares, such as accepting subscriptions within a limited time, in specific locations, or the need to pay additional fees.<\/p>\n\n\n\n

For this reason, the Issuer advises all persons entitled to submit Subscriptions for Series N Shares to familiarize themselves in advance with the terms and conditions for accepting subscriptions by brokerage houses maintaining their securities accounts or brokerage houses indicated by banks maintaining their securities accounts.<\/p>\n\n\n\n

If not all Series N Shares are taken up under the preemptive right and after taking into account additional subscriptions, any subscriptions for the remaining Series N Shares submitted by investors selected by the Management Board will be accepted from July 23, 2024, to August 6, 2024. Pursuant to Article 436 \u00a7 1-3 of the Commercial Companies Code, Series N Shares will be allocated by the Issuer’s Management Board at its discretion, but at a price not lower than their issue price.<\/p>\n\n\n\n

If, in the exercise of preemptive rights and after taking into account additional subscriptions, not all Series N Shares are subscribed for, any subscriptions for the remaining Series N Shares submitted by investors selected by the Management Board will be accepted by Dom Maklerski INC S.A. (the Intermediary) in a manner agreed with the Intermediary.<\/p>\n\n\n\n

DISCLAIMER<\/h2>\n\n\n\n

The public offering of Proacta S.A. Shares is conducted:<\/p>\n\n\n\n

on the basis of the Offering Document available at the link below,<\/p>\n\n\n\n

exclusively within the territory of the Republic of Poland.<\/p>\n\n\n\n

Outside the territory of the Republic of Poland, the Offering Document may not be treated as a proposal to purchase or an offer to sell Shares, or as an intention to solicit offers to purchase Shares in any other jurisdiction where such actions would be contrary to applicable regulations.<\/p>\n\n\n\n

The information and documents posted on this website are not intended for publication or distribution outside the territory of the Republic of Poland. The Offering Document and the shares covered by it have not been registered, approved or notified in any country other than the Republic of Poland, in particular in the United States of America.<\/p>\n\n\n\n

By using any of the links below, you confirm that you:<\/p>\n\n\n\n

are not located in the United States of America or in any other country whose laws prohibit the viewing of such materials,<\/p>\n\n\n\n

are not a resident of the United States (U.S. Person) within the meaning of Regulation S, which is an executive act to the U.S. Securities Act of 1933, as amended, and does not represent or act on behalf of such a person,<\/p>\n\n\n\n

has read and understood the above disclaimers.<\/p>\n\n\n\n

If you have any questions, please contact us using the form available at www.dminc.pl\/kontakt, entering \u201cProacta S.A. Offer\u201d in the subject line.<\/p>\n<\/div><\/div>\n","protected":false},"excerpt":{"rendered":"

This material is for promotional and informational purposes only and in no way constitutes a recommendation to purchase shares or a basis for deciding to acquire shares in Proacta S.A. The Offering Document, prepared in connection with the public offering of Proacta S.A. shares, is the only legally binding document containing information about the Company […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"templates\/offert.php","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-2055","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/proacta.pl\/en\/wp-json\/wp\/v2\/pages\/2055","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/proacta.pl\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/proacta.pl\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/proacta.pl\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/proacta.pl\/en\/wp-json\/wp\/v2\/comments?post=2055"}],"version-history":[{"count":1,"href":"https:\/\/proacta.pl\/en\/wp-json\/wp\/v2\/pages\/2055\/revisions"}],"predecessor-version":[{"id":2072,"href":"https:\/\/proacta.pl\/en\/wp-json\/wp\/v2\/pages\/2055\/revisions\/2072"}],"wp:attachment":[{"href":"https:\/\/proacta.pl\/en\/wp-json\/wp\/v2\/media?parent=2055"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}